[ ]

Реестр препаратов-кандидатов для лечения и профилактики COVID-19

Найдено 102 препаратов-кандидатов
Международное непатентованное наименование Канакинумаб (Canakinumab)
Торговое наименование Ilaris
Производитель, страна Novartis, Switzerland
Механизм действия

Canakinumab is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

Текущих КИ по COVID-19 5
Международное непатентованное наименование Клевудин (Clevudine)
Торговое наименование Levovir, Revovir
Производитель, страна Bukwang Pharmaceutical, The Republic of Korea
Механизм действия

Clevudine is an antiviral nucleoside analog drug. Upon entry into the cell, it is phosphorylated to its active state where it is incorporated into viral DNA in competition with the common nucleotide thymidine. Incorporation by viral polymerase leads to early DNA chain termination and thus non-viable viral progeny.

Текущих КИ по COVID-19 1
Международное непатентованное наименование Кобицистат (Cobicistat)
Торговое наименование Tybost
Производитель, страна Gilead Sciences, USA
Механизм действия

Cobicistat inhibits the human CYP3A proteins, which are known to degrade important antiretroviral molecules. Cobicistat is thus importantly used in combination with other drugs to help enhance their efficacy.


Cobicistat is effectively eliminate the anti-HIV activity of ritonavir while preserving its inhibitory effects on the CYP3A isozyme family of proteins. Cobicistat is therefore able to increase plasma concentration of other coadministered anti-HIV drugs without the risk of causing cobicistat-resistant mutations in the HIV virus.


FDA-approved since 2015, approved to treat HIV-1 infection.

Текущих КИ по COVID-19 2
Международное непатентованное наименование Кортикостероиды (Сorticosteroids)
Торговое наименование -
Производитель, страна -
Механизм действия

Кортикостероиды - гормоны коры надпочечников применяются как: 

  • противовоспалительные
  • иммунодепрессанты
  • заместительная терапия 
Текущих КИ по COVID-19 19
Международное непатентованное наименование Левилимаб (BCD-089, моноклональное антитело против рецептора интерлейкина-6)
Торговое наименование -
Производитель, страна БИОКАД, Россия
Механизм действия

Levilimab (formerly BCD 089) is a fully human antibody acting against the interleukin-6 receptor (IL-6R) being developed for the treatment of Rheumatoid arthritis.

Статус препарата

Зарегистрирован в РФ по ускоренной процедуре согласно Постановлению Правительства РФ от 3 апреля 2020 г. № 441.

Текущих КИ по COVID-19 1
Международное непатентованное наименование Леронлимаб (Leronlimab; PRO 140)
Торговое наименование -
Производитель, страна CytoDyn Inc., Canada
Механизм действия

Investigational Humanized Monoclonal Antibody to the Chemokine Receptor CCR5. Leronlimab may enhance immune response while mitigating cytokine storm.


The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

Текущих КИ по COVID-19 2
Международное непатентованное наименование Лозартан (Losartan)
Торговое наименование Cozaar, Лозартан
Производитель, страна Merck Sharp & Dohme, Netherlands; Нижфарм, Россия; Атолл, Россия; Sanofi, France; и др.
Механизм действия

Losartan is a selective, competitive angiotensin II receptor type 1 (AT1) antagonist, reducing the end organ responses to angiotensin II. Losartan administration results in a decrease in total peripheral resistance (afterload) and cardiac venous return (preload). All of the physiological effects of angiotensin II, including release of aldosterone, are antagonized in the presence of losartan. Reduction in blood pressure occurs independently of the status of the renin–angiotensin system. As a result of losartan dosing, plasma renin activity increases due to removal of the angiotensin II feedback. 


Текущих КИ по COVID-19 7
Международное непатентованное наименование Лопинавир + Ритонавир (Lopinavir&Ritonavir)
Торговое наименование Калерта, Калидавир, Лопирита
Производитель, страна AbbVie Deutschland GmbH & Co. KG, Germany; Фармасинтез, Россия; Нанофарма Девелопмент, Россия; Атолл, Россия; Lok-Beta Pharmaceuticals Pvt. Ltd., India
Механизм действия

Lopinavir and ritonavir may bind to Mpro, a key enzyme for coronavirus replication. This may suppress coronavirus activity.

Текущих КИ по COVID-19 18
Международное непатентованное наименование Мезенхимальные стволовые клетки (Mesenchymal stem cells)
Торговое наименование -
Производитель, страна -
Механизм действия

Many of the early clinical successes using intravenous transplantation came in systemic diseases such as graft versus host disease and sepsis. Direct injection or placement of cells into a site in need of repair may be the preferred method of treatment, as vascular delivery suffers from a "pulmonary first pass effect" where intravenous injected cells are sequestered in the lungs.

Текущих КИ по COVID-19 16
Международное непатентованное наименование Меплазумаб (Meplazumab)
Торговое наименование Ketantin
Производитель, страна Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd, China
Механизм действия

Meplazumab (Ketantin®) is a lyophilized powder for injection of small volume. The main active ingredient of the product, meplazumab, is a humanized immunoglobulin (Ig) G2 monoclonal antibody, consisting of the complementary-determining regions of anti CD147 murine antibody and the human framework region. It acts as an erythrocytic stage-macromolecular antibody drug that has the potential to mediate both treatment and prophylaxis of falciparum malaria.

Текущих КИ по COVID-19 1